Immune checkpoint inhibitors targeting PD-1/PD-L1 complex have shown promising results in several cancer types including melanoma, renal cell carcinoma, non-small cell lung cancer (NSCLC), and head and neck cancer [17]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.